Back to search
FDAFDA · Food and drugs·Recall number D-0042-2024

BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04

Published October 18, 2023 · Recall initiated: September 25, 2023

Summary

FDA records drug Class I recall D-0042-2024, published October 18, 2023 and initiated September 25, 2023. Recalling firm: Scynexis, Inc.; Status: Completed; Reported quantity: 17,376; Lot: Lot# LF21000008, Exp. 11/30/2023 Lot# LF22000051, Exp. 11/30/2025. Class I means a reasonable probability of serious adverse health consequences or death.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).

What to do

Voluntary: Firm initiated · E-Mail

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Scynexis, Inc.
Distributor
Nationwide in the US.
Lot
Lot# LF21000008, Exp. 11/30/2023 Lot# LF22000051, Exp. 11/30/2025
Risk classification
Class I
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04 recalled?

Yes. FDA published recall D-0042-2024 on October 18, 2023. Reported hazard: Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).

What should I do if I have this product?

Voluntary: Firm initiated · E-Mail